1581 related articles for article (PubMed ID: 26341644)
1. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
2. Local therapy for triple-negative breast cancer: a comprehensive review.
Grubb W; Young R; Efird J; Jindal C; Biswas T
Future Oncol; 2017 Aug; 13(19):1721-1730. PubMed ID: 28776394
[TBL] [Abstract][Full Text] [Related]
3. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
6. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
7. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
8. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
[TBL] [Abstract][Full Text] [Related]
10. [Non-metastatic triple-negative breast cancer in 2016: Definitions and management].
Portha H; Jankowski C; Cortet M; Desmoulins I; Martin E; Lorgis V; Arnould L; Coutant C
Gynecol Obstet Fertil; 2016 Sep; 44(9):492-504. PubMed ID: 27451066
[TBL] [Abstract][Full Text] [Related]
11. An overview of triple negative breast cancer for surgical oncologists.
Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
[TBL] [Abstract][Full Text] [Related]
12. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
14. Management of positive margins after initial lumpectomy in elderly women with breast cancer.
Angarita FA; Acuna SA; McCready DR; Escallon J
Eur J Surg Oncol; 2018 Jul; 44(7):1048-1053. PubMed ID: 29525464
[TBL] [Abstract][Full Text] [Related]
15. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
16. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype.
McGuire A; Lowery AJ; Kell MR; Kerin MJ; Sweeney KJ
Ann Surg Oncol; 2017 Oct; 24(11):3124-3132. PubMed ID: 28755141
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
18. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
[TBL] [Abstract][Full Text] [Related]
19. Quadruple-negative breast cancer: novel implications for a new disease.
Bhattarai S; Saini G; Gogineni K; Aneja R
Breast Cancer Res; 2020 Nov; 22(1):127. PubMed ID: 33213491
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
